Study identifier:D1950C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-fertile Female, young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses
Healthy
Phase 1
Yes
AZD1446, Placebo
All
80
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study is designed to evaluate the safety, tolerability and PK of AZD1446 in Subjects when given as multiple dose administration for either 7 Days (Day 1 single dose, Day 2-6 multiple doses) in Part A and optionally at fractionated doses for 1 Day in Part B.
Location
Location
Goteborg, Sweden
Location
Stockholm, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 1 Part A single and multiple dose and part B fractionated dose | Drug: AZD1446 Solution, oral single and multiple dose |
Placebo Comparator: 2 | Drug: Placebo Placebo |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.